Sandoz Accuses Eli Lilly Of Inequitable Conduct

Law360, New York (October 12, 2007, 12:00 AM EDT) -- Generic pharmaceutical company Sandoz Inc. is fighting back against Eli Lilly & Co. in an infringement battle over a patent for attention-deficit hyperactivity disorder treatment Strattera, denying the drug maker’s claims of infringement and asserting the patent-in-suit is invalid because of inequitable conduct.

In an answer and counterclaim filed Thursday in the U.S. District Court for the District of New Jersey, Sandoz alleged that Lilly’s patent describing methods for treating ADHD with atomoxetine is invalid because the drug maker withheld prior art from U.S. Patent and...
To view the full article, register now.